Companies:64432
FatCapitalist:Apple Inc. [AAPL]United States

Arch Biopartners Inc. [ACHFF]Canada

Other OTC exchange. Sector: Healthcare. Industry: Biotechnology. Location Canada, Toronto.
At close Mon Sep 26 2022
2.15 USD 👎0.05 (-2.33%)

At close Mon Sep 26 2022

Marketcap
134,337,600 USD

Marketcap

PE:.
BETA (5y):1.101
EPS:-0.075
Profits

for 5 years

605%

for 3 years

125%

for 2 years

213%

for 1 year

122%

for this year

-16%
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

Arch Biopartners Inc.
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.